What is Immunovative Therapies?
Immunovative Therapies, Ltd. (ITL) is an Israeli biopharmaceutical firm dedicated to the advancement, production, and evaluation of innovative immunotherapy treatments. A key subsidiary, ImmunoCare, Ltd., holds exclusive worldwide marketing rights for CryoVax® in the colorectal cancer market. Founded in May 2004 with foundational support from the Israel Office of the Chief Scientist and Hadassah-Hebrew University Medical Center, ITL operates globally with facilities in Jerusalem, Phoenix, AZ, USA, and Thailand. The company's core focus is on pioneering new therapeutic avenues in cancer treatment through advanced immunotherapy.
How much funding has Immunovative Therapies raised?
Immunovative Therapies has raised a total of $12M across 1 funding round:
Unspecified
$12M
Unspecified (2012): $12M with participation from Trendlines Group and Misgav Technology Center
Key Investors in Immunovative Therapies
Trendlines Group
Trendlines Group is an investment company focused on inventing, discovering, investing in, and incubating medtech and agrifood technologies to improve the human condition. They are known for their hands-on approach to portfolio companies, assisting in technology development and business building.
Misgav Technology Center
Misgav Venture Accelerator is dedicated to investing in and building medical technology businesses, leveraging experienced management with strong connections to the Israeli and international business communities. They focus on commercializing products, raising capital, and building businesses within the medical technology sector.
What's next for Immunovative Therapies?
With the recent major strategic investment, Immunovative Therapies is poised for accelerated growth and market expansion. The enterprise-level capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support broader clinical trials. This strategic backing will likely enable ITL to solidify its market position and advance its pipeline of novel immunotherapy products, particularly CryoVax® for colorectal cancer, towards commercialization and wider patient access. The company's trajectory indicates a strong focus on translating scientific innovation into tangible therapeutic solutions.
See full Immunovative Therapies company page
